title: [A case of emergency operation for pedicle torsion of ovarian tumor during bevacizumab therapy].
abstract: We report a case of torsion of ovarian carcinoma pedicle during chemotherapy with bevacizumab and FOLFIRI. A 47-year-old-female who had undergone laparoscopic-assisted sigmoidectomy for sigmoid cancer with multiple metastatic liver tumors, was treated with 3 courses of FOLFOX4 and 9 courses of FOLFIRI. Bevacizumab (BV) was started to administer with FOLFIRI since a CT scan had revealed that metastatic liver tumors had enlarged . Four days after final administration of BV (13th course), she presented lower abdominal pain. CT scan showed an enlarged right ovary sized 20 cm, but no findings suggesting bowel perforation; therefore we assumed her pain was due to enlarged ovarian tumor, which might be metastasis from sigmoid cancer. Increased oral morphine could not relieve her pain. Then, along with sufficient information about the risks of the operation caused by BV, we proposed an operation to remove her enlarged ovary. Day 16 after final administration of BV, we undertook a laparotomy by lower median incision, and found a twisted right adnex with large necrotic ovarian tumor. Pathologists diagnosed the ovarian tumor as primary ovarian cancer. No complication related to BV occurred, and she was moved to the ward for internal medicine 13 days after operation.
authors.affiliation: Dept. of Surgery, Sapporo General Pathology Laboratory, Japan.
authors.forename: Soichi
authors.initials: S
authors.lastname: Murakami
authors.forename: Makoto
authors.initials: M
authors.lastname: Omi
authors.forename: Atsuya
authors.initials: A
authors.lastname: Yonemori
authors.forename: Takumi
authors.initials: T
authors.lastname: Yamabuki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hayama
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Inomata
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Nihei
authors.forename: Toshie
authors.initials: T
authors.lastname: Yonehara
authors.forename: Shigeharu
authors.initials: S
authors.lastname: Sugimoto
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hori
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Fujisawa
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000601:surgery*; D012811:Sigmoid Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D054159:Torsion, Mechanical
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab